At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 9 enrolled
Drug / intervention
Radio pharmaceuticals C-11 Acetate, and C-11 Palmitatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Interdisciplinary Approach to the Study of Non-alcoholic Fatty Liver Disease
In Brief
A Early Phase 1 clinical trial evaluating Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate for Fatty Liver. Completed, enrolled 9 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate how the liver receives and uses fats for energy. This will help the investigators further understand the physical and chemical processes responsible for Non-Alcoholic Fatty Liver Disease (NAFLD) in overweight females with or without NAFLD who are scheduled to undergo gastric bypass surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFatty Liver
CountriesUnited States
CollaboratorsBarnes-Jewish Hospital
Timeline
Early Ph 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartJul 2010
Primary CompletionJan 2011
Study CompletionJan 2011
TodayJul 2026
First PostedJul 30, 2009
Enrollment StartJul 1, 2010
Primary CompletionJan 1, 2011
Study CompletionJan 19, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.9 years ago
Interventions
Radio pharmaceuticals C-11 Acetate, and C-11 Palmitatedrug
injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism